Log In
BCIQ
Print this Print this
 

AT307 (formerly AT003, CASQ2-CPVT)

  Manage Alerts
Collapse Summary General Information
Company Audentes Therapeutics Inc.
DescriptionAdeno-associated virus (AAV) vector-based therapy that delivers calsequestrin 2 (CASQ2) gene to cardiomyocytes
Molecular Target Calsequestrin 2 (CASQ2)
Mechanism of ActionGene therapy
Therapeutic ModalityGene therapy: Viral vector: Adeno-associated virus (AAV)
Latest Stage of DevelopmentPreclinical
Standard IndicationTachycardia
Indication DetailsTreat catecholaminergic polymorphic ventricular tachycardia (CPVT) in patients harboring inherited mutations in the CASQ2 gene
Regulatory Designation
Partner

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
Total Number of DealsTotal Deal ValueTotal Upfront CashTotal Milestone Payments

1

0

0

0


 Deals Details
DateCompanies InvolvedDeal HeadlineTotal Deal ValueTotal Upfront CashTotal Milestone

09/01/2015

Undisclosed

Undisclosed

Undisclosed

Get a free BioCentury trial today